Compare C3.ai Inc (AI) vs Novavax Inc (NVAX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
C3.ai Inc vs Novavax Inc — how do they compare? C3.ai Inc trades at $8.85 (market cap $1.39B), while Novavax Inc trades at $9.33 (market cap $1.56B). The key difference: C3.ai Inc and Novavax Inc are close in size by market cap, and Novavax Inc is trading nearer its 52-week high, C3.ai Inc nearer its low. Which is the better fit depends on your goals.
| AI | NVAX | |
|---|---|---|
Market Cap | $1.39B | $1.56B |
Sector | Technology | Health |
52-Week High | $29.16 | $11.19 |
52-Week Low | $7.76 | $6.22 |
Enterprise Value | $818.29M | $1.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
C3.ai trades at $8.93, down 1.43% with bearish technical signals. The company shows revenue growth to $389M in 2025 but continues significant losses with -$289M net income. Analyst sentiment is mixed with 21% buy ratings and consensus target of $10.20. Recent developments include board member Jim Hagemann Snabe's appointment as European Commission Special Envoy for Industrial AI.
While revenue growth presents opportunity, persistent losses and negative cash flow pose substantial risk. The stock faces headwinds from unprofitability despite beating some earnings estimates. Upside potential exists if the company can accelerate path to profitability amid growing enterprise AI adoption.
Novavax (NVAX) trades at $9.46, down 2.87% on the day, with a bullish technical signal from moving averages. The company reported strong revenue of $1.12B in 2025 and has beaten EPS estimates for three consecutive quarters. Analyst consensus is bullish with a $14.00 price target, though negative cash flow and shareholder equity remain concerns. Recent news highlights investor attention and participation in healthcare conferences.
Outlook: Potential upside exists from continued earnings beats and vaccine demand, but risks include persistent cash burn, high debt, and competitive pressures. The stock offers speculative growth opportunity amid volatile biotech sentiment, requiring careful risk assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About C3.ai Inc
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Suite, is a comprehensive application development and runtime environment that is designed to allow customers to rapidly design, develop, and deploy Enterprise AI applications of any type
Read more on AI →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
